表紙
市場調查報告書

全球溫韋伯氏疾病治療市場:2020年∼2024年

Global Von Willebrand Disease Therapeutics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 955193
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球溫韋伯氏疾病治療市場:2020年∼2024年 Global Von Willebrand Disease Therapeutics Market 2020-2024
出版日期: 2020年08月27日內容資訊: 英文 120 Pages
簡介

全球溫韋伯氏疾病治療市場在2020年∼2024年的預測期間內,預計將以6%的年複合成長率推移,並成長到1億6548萬美元。近年來,越來越多的患者支持計劃和產品批准增加,推動了該市場的成長。

本報告提供全球溫韋伯氏疾病治療市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各產品市場區隔

  • 市場區隔
  • 各產品比較
  • 去氨加壓素-市場規模與預測2019-2024
  • 補充療法-市場規模與預測2019-2024
  • 其他-市場規模與預測2019-2024
  • 各產品市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美 -市場規模與預測2019-2024
  • 歐洲-市場規模與預測2019-2024
  • 亞太地區-2019-2024市場規模與預測
  • 其他地區-市場規模與預測2019-2024
  • 主要國家
  • 地區的市場機會
  • 市場成長要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 市場形勢的阻礙

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Apotex Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • CSL Ltd.
  • Ferring Pharmaceuticals AS
  • Glenmark Pharmaceuticals Ltd.
  • Grifols SA
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

附錄

目錄
Product Code: IRTNTR44703

Technavio has been monitoring the Von Willebrand Disease Therapeutics market and it is poised to grow by $ 165.48 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period. Our reports on Von Willebrand Disease Therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in patient assistance programs and recent product approvals. In addition, increase in patient assistance programs is anticipated to boost the growth of the market as well.

The Von Willebrand Disease Therapeutics market analysis includes product segment and geographic landscapes.

Technavio's ‘Von Willebrand Disease Therapeutics market ’ is segmented as below:

By Product:

  • Desmopressin
  • Replacement therapy
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • APAC
  • ROW

This study identifies by the special regulatory designations as one of the prime reasons driving the Von Willebrand disease therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our Von Willebrand Disease Therapeutics market covers the following areas:

  • Von Willebrand Disease Therapeutics market sizing
  • Von Willebrand Disease Therapeutics market forecast
  • Von Willebrand Disease Therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, the report provides a detailed analysis of several leading Von Willebrand Disease Therapeutics market vendors that include Apotex Inc., Baxter International Inc., Bio Products Laboratory Ltd., CSL Ltd., Ferring Pharmaceuticals AS, Glenmark Pharmaceuticals Ltd., Grifols SA, Octapharma AG, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Also, the Von Willebrand Disease Therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Desmopressin - Market size and forecast 2019-2024
  • Replacement therapy - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Apotex Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • CSL Ltd.
  • Ferring Pharmaceuticals AS
  • Glenmark Pharmaceuticals Ltd.
  • Grifols SA
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Product - Market share 2019-2024 (%)
  • 22: Comparison by Product
  • 23: Desmopressin - Market size and forecast 2019-2024 ($ million)
  • 24: Desmopressin - Year-over-year growth 2019-2024 (%)
  • 25: Replacement therapy - Market size and forecast 2019-2024 ($ million)
  • 26: Replacement therapy - Year-over-year growth 2019-2024 (%)
  • 27: Others - Market size and forecast 2019-2024 ($ million)
  • 28: Others - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Product
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: North America - Market size and forecast 2019-2024 ($ million)
  • 44: North America - Year-over-year growth 2019-2024 (%)
  • 45: Europe - Market size and forecast 2019-2024 ($ million)
  • 46: Europe - Year-over-year growth 2019-2024 (%)
  • 47: APAC - Market size and forecast 2019-2024 ($ million)
  • 48: APAC - Year-over-year growth 2019-2024 (%)
  • 49: ROW - Market size and forecast 2019-2024 ($ million)
  • 50: ROW - Year-over-year growth 2019-2024 (%)
  • 51: Impact of drivers and challenges
  • 52: Vendor landscape
  • 53: Landscape disruption
  • 54: Industry risks
  • 55: Vendors covered
  • 56: Market positioning of vendors
  • 57: Apotex Inc. - Overview
  • 58: Apotex Inc. - Product and service
  • 59: Apotex Inc. - Key offerings
  • 60: Apotex Inc. - Key customers
  • 61: Apotex Inc. - Segment focus
  • 62: Baxter International Inc. - Overview
  • 63: Baxter International Inc. - Business segments
  • 64: Baxter International Inc. - Key offerings
  • 65: Baxter International Inc. - Key customers
  • 66: Baxter International Inc. - Segment focus
  • 67: Bio Products Laboratory Ltd. - Overview
  • 68: Bio Products Laboratory Ltd. - Product and service
  • 69: Bio Products Laboratory Ltd. - Key offerings
  • 70: Bio Products Laboratory Ltd. - Key customers
  • 71: Bio Products Laboratory Ltd. - Segment focus
  • 72: CSL Ltd. - Overview
  • 73: CSL Ltd. - Business segments
  • 74: CSL Ltd. - Key offerings
  • 75: CSL Ltd. - Key customers
  • 76: CSL Ltd. - Segment focus
  • 77: Ferring Pharmaceuticals AS - Overview
  • 78: Ferring Pharmaceuticals AS - Product and service
  • 79: Ferring Pharmaceuticals AS - Key offerings
  • 80: Ferring Pharmaceuticals AS - Key customers
  • 81: Ferring Pharmaceuticals AS - Segment focus
  • 82: Glenmark Pharmaceuticals Ltd. - Overview
  • 83: Glenmark Pharmaceuticals Ltd. - Product and service
  • 84: Glenmark Pharmaceuticals Ltd. - Key offerings
  • 85: Glenmark Pharmaceuticals Ltd. - Key customers
  • 86: Glenmark Pharmaceuticals Ltd. - Segment focus
  • 87: Grifols SA - Overview
  • 88: Grifols SA - Business segments
  • 89: Grifols SA - Key offerings
  • 90: Grifols SA - Key customers
  • 91: Grifols SA - Segment focus
  • 92: Octapharma AG - Overview
  • 93: Octapharma AG - Product and service
  • 94: Octapharma AG - Key offerings
  • 95: Octapharma AG - Key customers
  • 96: Octapharma AG - Segment focus
  • 97: Pfizer Inc. - Overview
  • 98: Pfizer Inc. - Business segments
  • 99: Pfizer Inc. - Key offerings
  • 100: Pfizer Inc. - Key customers
  • 101: Pfizer Inc. - Segment focus
  • 102: Takeda Pharmaceutical Co. Ltd. - Overview
  • 103: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 104: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 105: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 106: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 107: Currency conversion rates for US$
  • 108: Research Methodology
  • 109: Validation techniques employed for market sizing
  • 110: Information sources
  • 111: List of abbreviations